Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.

Saved in:
Bibliographic Details
Title: Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Authors: Collins DM; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Leinster, Ireland. denis.collins@dcu.ie., Madden SF; RCSI Division of Population Health Sciences, Royal College of Surgeons in Ireland, Beaux Lane House, Dublin, Ireland., Gaynor N; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Leinster, Ireland., AlSultan D; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Leinster, Ireland.; RCSI Division of Population Health Sciences, Royal College of Surgeons in Ireland, Beaux Lane House, Dublin, Ireland., Le Gal M; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Leinster, Ireland., Eustace AJ; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Leinster, Ireland., Gately KA; Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, St. James's Hospital, Dublin, Ireland., Hughes C; Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, St. James's Hospital, Dublin, Ireland., Davies AM; Trinity Translational Medicine Institute, Trinity Centre for Health Sciences, St. James's Hospital, Dublin, Ireland., Mahgoub T; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Leinster, Ireland., Ballot J; Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland., Toomey S; RCSI Molecular Medicine, Royal College of Surgeons in Ireland, RCSI Education & Research Centre, Beaumont Hospital, Beaumont, Dublin, Ireland., O'Connor DP; Royal College of Surgeons in Ireland, School of Pharmacy & Biomolecular Science, Dublin, Ireland., Gallagher WM; UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland., Holmes FA; Texas Oncology-Memorial Hermann Memorial City, US Oncology Research, Houston, -Texas., Espina V; Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia., Liotta L; Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia., Hennessy BT; RCSI Molecular Medicine, Royal College of Surgeons in Ireland, RCSI Education & Research Centre, Beaumont Hospital, Beaumont, Dublin, Ireland.; Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland., O'Byrne KJ; Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology, Brisbane, Queensland, Australia., Hasmann M; Roche Innovation Center Penzberg, Roche Diagnostics GmbH, Penzberg, Germany., Bossenmaier B; Pieris Pharmaceuticals, Inc., Boston, Massachusetts., O'Donovan N; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Leinster, Ireland., Crown J; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Leinster, Ireland.; Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Feb 01; Vol. 27 (3), pp. 807-818. Date of Electronic Publication: 2020 Oct 29.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-20-2007